Who
Heidi Fields
Director
Company insider
Files Form 4 as: Director, Phathom Pharmaceuticals; Director, Agilent Technologies; Director and Other, Icosavax; Director, Avanos Medical; Director, Financial Engines.
In numbers
- Trades disclosed
- 162
- Buys
- 3
- Sells
- 18
- Bought
- $83K
- Sold
- $7.8M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 2 Mar 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 14 Mar 2025filed 18 Mar 2025 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $220K1,819 at $121.18 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 15 Mar 2024filed 19 Mar 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $247K1,678 at $147.48 | filing |
| 5 Mar 2024filed 7 Mar 2024 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $239K1,658 at $144.34 | filing |
| 19 Feb 2024filed 20 Feb 2024 | Icosavaxoption or derivative | SEC FORM 4 Code D | —22,278 | filing |
| 19 Feb 2024filed 20 Feb 2024 | Icosavaxoption or derivative | SEC FORM 4 Code D | —25,266 | filing |
| 19 Feb 2024filed 20 Feb 2024 | Icosavaxoption or derivative | SEC FORM 4 Code D | —17,000 | filing |
| 19 Feb 2024filed 20 Feb 2024 | Icosavax | SEC FORM 4 Code U | —11,376 | filing |
| 19 Feb 2024filed 20 Feb 2024 | Icosavax | SEC FORM 4 Code D | —2,917 | filing |
| 6 Jun 2023filed 8 Jun 2023 | Icosavaxoption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 16 Mar 2023filed 20 Mar 2023 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Code A | $227K1,658 at $136.82 | filing |
| 23 Nov 2022filed 28 Nov 2022 | A Agilent TechnologiesLife-science tools | SEC FORM 4 Sold | $566K3,635 at $155.84 | filing |
| 10 Jun 2022filed 14 Jun 2022 | Icosavaxoption or derivative | SEC FORM 4 Code A | —22,278 at $0.00 | filing |
News
Agilent Technologies, Inc. $A Stock: Stone Summit Wealth LLC Lowers HoldingsA · dailypolitical.com · 14 Oct 2026Agilent Technologies: Agilent to buy pathology software maker Proscia for $240 millionA · indiatimes.com · 13 Oct 2026
0 headlines in the last 90 days name Heidi Fields; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.